Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
1(5%)
Results Posted
20%(2 trials)

Phase Distribution

Ph phase_3
4
21%
Ph phase_4
7
37%
Ph phase_1
1
5%
Ph phase_2
5
26%

Phase Distribution

1

Early Stage

5

Mid Stage

11

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
1(5.9%)
Phase 2Efficacy & side effects
5(29.4%)
Phase 3Large-scale testing
4(23.5%)
Phase 4Post-market surveillance
7(41.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

19

all time

Status Distribution
Active(1)
Completed(10)
Terminated(2)
Other(6)

Detailed Status

Completed10
unknown6
Withdrawn2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (5.9%)
Phase 25 (29.4%)
Phase 34 (23.5%)
Phase 47 (41.2%)

Trials by Status

recruiting15%
unknown632%
withdrawn211%
completed1053%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT03264352Phase 4

Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes

Recruiting
NCT04692467Phase 2

Treatment of Early Hypertension Among Persons Living With HIV in Haiti

Completed
NCT02368665Phase 3

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

Completed
NCT04954196Phase 2

Benefit of Amlodipine in HRT Cycle for Frozen Embryo Transfer in the Correction of Uterine Pulsatility Index

Withdrawn
NCT05165251Phase 4

Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension

Unknown
NCT04474899Phase 4

Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

Unknown
NCT03666351Phase 4

Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease

Completed
NCT04554303

Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension

Unknown
NCT03978884Phase 4

Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes

Withdrawn
NCT02651870Phase 3

Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

Completed
NCT03489317

Gut Microbiomes in Patients With Metabolic Syndrome

Unknown
NCT02944734Phase 2

Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

Completed
NCT02586311Phase 3

CKD-330 Phase 3 Trial in Amlodipine Non-responder

Completed
NCT02548286Phase 1

Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs

Completed
NCT02206165Phase 2

A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension

Unknown
NCT01103960Phase 3

An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy

Completed
NCT02059616Phase 2

A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension

Unknown
NCT00819104Phase 4

A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components

Completed
NCT00426478Phase 4

Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19